Conduritol

Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update

Retrieved on: 
Thursday, November 10, 2022

BETHESDA, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced its financial results for the third quarter ended September 30, 2022, and highlighted recent corporate progress.

Key Points: 
  • The latest preclinical data provide further validation of the potential utility of our approach and mechanism of action of GT-02287.
  • If these results are supported in our upcoming clinical trials, we believe that GT-02287 could become a potential first-in-class disease-modifying therapy for Parkinsons disease.
  • Presented new preclinical data for GT-02287, Gains lead compound for Parkinsons Disease at the International Congress of Parkinsons Disease and Movement Disorders 2022 Annual Meeting.
  • Cash, cash equivalents and marketable securities were $25.7 million as of September 30, 2022 compared to $36.8 million at December 31, 2021.

Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson’s Disease

Retrieved on: 
Monday, September 19, 2022

BETHESDA, Md., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational drug discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced the presentation of new preclinical data at the International Congress of Parkinson’s Disease and Movement Disorders 2022 Annual Meeting in Madrid, Spain, evaluating the neuroprotective effect of Gain’s lead ‘Structurally Targeted Allosteric Regulator’ (STAR) compound, GT-02287, in preclinical in vitro and in vivo models of Parkinson’s disease.

Key Points: 
  • We are especially excited by these latest data which expand on the accumulating preclinical evidence supporting the potential disease-modifying properties of our novel small molecule candidate, GT-02287, said Joanne Taylor, Ph.D., Senior Vice President of Research at Gain Therapeutics.
  • If these results are supported in future clinical studies, GT-02287 could become an important first-in-class disease-modifying therapy for Parkinsons disease.
  • In the first study, the ability of GT-02287 to neutralize CBE-mediated neurodegeneration was evaluated in rat mesencephalic neurons.
  • Mutations in the GBA1 gene, encoding the lysosomal enzyme GCase, represents the most common genetic risk factor for Parkinsons disease (PD).